Please assess the completion status of the following clinical trial:

Trial Title: Add-On Therapy to Risperidonein Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patient aged ≧18 and ≦60 years.~2. A diagnosis of schizophrenia or schizoaffective disorder according to DSM-IV criteria made by a specialist in psychiatry.~3. Acute exacerbation of schizophrenia.~4. A total of PANSS score of at least 60 at screen.~5. History of schizophrenia ≦ 15 years (from onset of prodromal symptoms).~6. Signed informed consent by patient or legal representative~7. Patient or a reliable caregiver can be expected to ensure acceptable compliance and visit attendance for the duration of the study.~Exclusion Criteria:~1. Women of childbearing potential not using adequate contraception as per investigator judgement or not willing to comply with contraception for duration of study.~2. Less than a full cycle has lapsed at time of screening following the last injection of a depot antipsychotic~3. Females who are pregnant or nursing.~4. Patient has received dextromethorphan, or other selective cyclo- oxygenase 2 inhibitors, or other anti-inflammatory medication within 1 week prior to first dose of double-blind medication.~5. Axis-I DSM-IV diagnosis other than schizophrenia or schizoaffective disorder.~6. Current evidence of an uncontrolled and/or clinically significant medical condition, e.g., cardiac, hepatic and renal failure that in the judgement of the investigator, would compromise patient safety or preclude study participation.~7. History of intolerance to risperidone or dextromethorphan or other Cox-2 inhibitors.~8. History of sensitivity reaction (e.g., urticaria, angioedema, bronchospasm, severe rhinitis, anaphylactic shock) precipitated by dextromethorphan.~9. Patient has received electroconvulsive therapy (ECT) within 4 weeks prior to first dose of double-blind medication.~10. Diagnosis of or treatment for oesophageal, gastric, pyloric channel, or duodenal ulceration or related complications (bleeding and/or perforation) within 30 days prior to receiving first dose of double-blind medication.~11. Inclusion in another schizophrenia study or study for another indication with psychotropics within the last 30 days prior to start of study.~12. Increase in total SGOT, SGPT, gamma-GT, BUN and creatinine by more than 3X ULN (upper limit of normal).~13. History of idiopathic or drug-induced agranulocytosis.~14. Alcohol, illegal or other substance-abuse within 6 months prior to study start, as defined by DSM-IV criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- dextromethorphan (Type: EXPERIMENTAL): Research clinical trial of double-blind, stratified randomized, parallel group, double-centre study

Based on this trial design, predict the completion outcome and termination type (if applicable).